Skip to main content
OpenTrials
Completed

NCT Number: NCT06709261

Safety and Performance of the OTTAVA Robotic System

This study assesses safety and performance of the OTTAVA Robotic System, through 30 days postoperative, in subjects undergoing robotic-assisted Roux-en-Y Gastric Bypass (RYGB) procedure.

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Orlando Health, Orlando, Florida, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Criteria for Inclusion:

  • Willing and able to provide informed consent;
  • Scheduled for an elective primary RYGB surgical procedure;
  • American Society of Anesthesiologists classification ≤ ASA III;
  • Body habitus such that the procedure can be safely completed with OTTAVA Robotic System;
  • Body weight <500 lb (227 kg);
  • Patient presenting with class 2 or 3 obesity (BMI ≥ 35), regardless of comorbidities, or obesity with health risk satisfying 2022 ASMBS/IFSO indications for bariatric surgery; and
  • A minimum of 21 years of age (at time of consent).

Criteria for Exclusion:

  • Surgeon determination that there is a medical condition, that makes surgery too risky, including intraoperative finding;
  • Concomitant surgical procedure including cholecystectomy (hiatal hernia repair up to 5 cm and adhesiolysis allowed);
  • Upper abdominal surgery within two years prior to enrollment (prior laparoscopic cholecystectomy allowed);
  • Evidence of hiatal hernia >5 cm (preoperative/intraoperative);
  • Enrolled in another investigational study that may confound the results of this study;
  • Emergency surgery;
  • Active pregnancy; or
  • Subject from a vulnerable population, including anyone unable to adequately provide informed consent.

Treatment and study plan

OTTAVA Robotic System

Device

Procedure with the OTTAVA Robotic System

Primary outcomes

  1. Procedure completion without conversion to open surgery

    Time frame: Procedure day

  2. Occurrence of intraoperative and postoperative device- or procedure-related complications

    Time frame: Through 30 days post-procedure

Secondary outcomes

  1. Occurrence of all adverse events

    Time frame: Through 30 days post-procedure

  2. Total operative time

    Time frame: Procedure day

  3. Estimated blood loss

    Time frame: Procedure day

  4. Occurrence of blood transfusion

    Time frame: Procedure day

  5. Device malfunction details

    Time frame: Procedure day

  6. Length of hospital stay

    Time frame: Hospital stay, assessed up to 30 days

  7. Hospital readmission

    Time frame: Through 30 days

  8. Reoperation

    Time frame: Through 30 days

  9. Anastomotic leak

    Time frame: Through 30 days

  10. Anastomotic stricture

    Time frame: Through 30 days

  11. Mortality

    Time frame: Through 30 days

Sponsors and collaborators

Lead sponsor

Auris Health, Inc.

Industry

Registry information

Official study title

EDS-2022-01: Safety and Performance of the OTTAVA™ Robotic System: A Prospective, Multi-Center Evaluation (FORTE)

Acronym: FORTE

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Nov 29, 2024
Registry last updated
Aug 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.